Celator Pharmaceuticals (CPXX) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	12-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'CPXX	'
Entity Common Stock, Shares Outstanding	'	26,078,532
Entity Registrant Name	'Celator Pharmaceuticals Inc	'
Entity Central Index Key	'0001327467	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$20,812,057	$23,589,516
Restricted cash	286,245	287,657
Other receivables	5,856	1,417,313
Prepaid expenses and deposits	172,075	491,465
Assets held for sale	74,086	74,086
Other current assets	484,320	468,389
Total current assets	21,834,639	26,328,426
Property and equipment, net	1,093,279	1,138,579
Other assets	35,687	5,745
Total assets	22,963,605	27,472,750
Current liabilities:	'	'
Accounts payable	1,068,168	1,193,148
Accrued liabilities	1,257,891	1,630,809
Current portion of deferred revenue	542,986	542,986
Total current liabilities	2,869,045	3,366,943
Deferred revenue	452,489	588,236
Deferred rent	51,464	53,084
Total liabilities	3,372,998	4,008,263
Stockholders' equity	'	'
Common stock Authorized 255,000,000 shares, par value $0.001 Issued and outstanding 26,078,532 and 26,035,596 shares as of March 31, 2014 and December 31, 2013 respectively	26,079	26,036
Warrants	1,083,193	1,083,193
Additional paid-in capital	156,357,472	155,953,894
Accumulated other comprehensive loss	-1,133,266	-1,133,266
Deficit accumulated during the development stage	-136,742,871	-132,465,370
Total stockholders' equity	19,590,607	23,464,487
Total liabilities and stockholders' equity	$22,963,605	$27,472,750

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common stock, authorized shares	255,000,000	255,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, issued shares	26,078,532	26,035,596
Common stock, outstanding shares	26,078,532	26,035,596

Consolidated_Statements_of_Los

Consolidated Statements of Loss and Comprehensive Loss (USD $)	3 Months Ended		173 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Expenses	'	'	'
Research and development	$2,967,853	$1,651,409	$92,808,574
Leukemia & Lymphoma Society funding	-635,747	-153,846	-6,653,255
Research collaboration income	0	0	-2,240,720
General and administrative	1,888,267	1,348,999	44,516,694
Loss on disposal of property and equipment	0	13,727	898,719
Amortization and depreciation	47,735	47,588	4,919,708
Operating loss	-4,268,108	-2,907,877	-134,249,720
Other income (expenses)	'	'	'
Foreign exchange (loss) gain	-11,708	-3,049	500,512
Interest and miscellaneous income	2,315	429	2,773,376
Gain on settlement in exchange of preferred stock	0	0	1,562,689
Non-cash derivative instrument charge	0	-6,725,797	-7,473,108
Interest expense	0	-47,654	-6,036,652
Loss before income taxes	-4,277,501	-9,683,948	-142,922,903
Income tax benefit	0	0	7,655,885
Net loss incurred in the development stage	-4,277,501	-9,683,948	-135,267,018
Other comprehensive loss attributable to foreign exchange translation	0	0	-1,133,266
Comprehensive loss	-4,277,501	-9,683,948	-136,400,284
Accretion on preferred stock	0	0	-1,475,853
Total comprehensive loss attributable to common stockholders	-4,277,501	-9,683,948	-137,876,137
Net loss incurred in the development stage	-4,277,501	-9,683,948	-135,267,018
Accretion on preferred stock	0	0	-1,475,853
Net loss attributable to common stockholders	($4,277,501)	($9,683,948)	($136,742,871)
Net loss per share	'	'	'
Basic and diluted (in dollars per share)	($0.16)	($0.71)	'
Weighted average of common shares outstanding	'	'	'
Basic and diluted (in shares)	26,037,504	13,673,160	'

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Warrants Amount [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Deficit Accumulated During The Development Stage [Member]
Balance at Dec. 31, 2013	$23,464,487	$26,036	$1,083,193	$155,953,894	($1,133,266)	($132,465,370)
Balance, shares at Dec. 31, 2013	'	26,035,596	'	'	'	'
Issued for cash on exercise of stock options	100,639	43	0	100,596	0	0
Issued for cash on exercise of stock options, shares	42,936	42,936	'	'	'	'
Stock based compensation	302,982	0	0	302,982	0	0
Net loss for the period	-4,277,501	0	0	0	0	-4,277,501
Balance at Mar. 31, 2014	$19,590,607	$26,079	$1,083,193	$156,357,472	($1,133,266)	($136,742,871)
Balance, shares at Mar. 31, 2014	'	26,078,532	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		173 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Operating activities	'	'	'
Net loss	($4,277,501)	($9,683,948)	($136,742,871)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Amortization and depreciation	47,735	47,588	4,919,708
Accretion on preferred stock	0	0	1,475,853
Non-cash stock-based compensation expense	302,982	4,276	1,960,777
Gain on settlement of preferred stock	0	0	-1,562,689
Loss on disposal of property and equipment	0	13,727	898,719
Non-cash derivative instrument charge	0	6,725,797	7,473,108
Non-cash financing costs	0	7,733	4,771,178
Changes in operating assets and liabilities	'	'	'
Other receivables	1,407,709	1,884,109	-5,856
Prepaid expenses and deposits	319,089	47,997	-172,376
Restricted cash	-13	-300,001	-250,062
Other current assets	-15,931	-440,000	-484,320
Other assets	-29,938	-63,109	-110,687
Accounts payable	-122,129	-101,786	1,070,063
Accrued liabilities	-365,909	747,494	1,277,095
Deferred rent liability	-1,620	0	51,464
Deferred revenue	-135,747	-153,846	995,475
Cash used in operating activities	-2,871,273	-1,263,969	-114,435,421
Investing activities	'	'	'
Purchase of property and equipment	-2,436	0	-7,432,956
Proceeds on disposals of property and equipment	0	29,976	447,164
Cash (used in) provided by investing activities	-2,436	29,976	-6,985,792
Financing activities	'	'	'
Proceeds from issuance of common stock and on options exercised	104,387	0	41,140,642
Proceeds from issuance of warrants and warrant derivatives	0	0	500
Proceeds from issuance of preferred stock	0	0	102,157,702
Payment of share issuance costs	0	0	-4,971,345
Proceeds from loans payable	0	0	17,898,295
Repayments of capital lease obligation	0	0	-163,242
Repayments of loans payable	0	-300,000	-12,735,054
Cash provided by (used in) financing activities	104,387	-300,000	143,327,498
Effect of foreign exchange rate changes	-8,137	-3,626	-1,094,228
Net change in cash	-2,777,459	-1,537,619	20,812,057
Cash and cash equivalents, beginning of period	23,589,516	9,648,008	0
Cash and cash equivalents, end of period	20,812,057	8,110,389	20,812,057
Supplemental disclosure of cash flow information	'	'	'
Interest paid	0	38,164	1,123,204
Income taxes paid	0	0	172,451
Property and equipment purchased under capital lease	0	0	449,744
Common stock issued on conversion of debt	0	0	6,842,144
Preferred stock issued on conversion of debt	$0	$0	$5,337,417

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Nature of Operations [Text Block]	'
	1	Nature of Business and Liquidity
	Celator Pharmaceuticals, Inc. (“CPI” or the “Company”), with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.
	The Company has incurred recurring losses and negative cash flows from operations since inception. As of March 31, 2014, the Company had an accumulated deficit of $136.7 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At March 31, 2014, the Company had cash and cash equivalents of $20.8 million. In May 2014, the Company entered into a term loan agreement for $15 million,$10 million of which was funded at closing, with Hercules Technology Growth Capital, Inc. (Hercules) (see Note 11). Management believes that the Hercules term loan and  cash and cash equivalents at March 31, 2014 will be sufficient to meet estimated working capital requirements and fund planned operations into the fourth quarter of 2015. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates.
	The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2	Summary of Significant Accounting Policies
	The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.
	In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
	Basis of consolidation: The consolidated financial statements include the accounts of Celator and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	3	Fair Value Measurements
	Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature.
	Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
	Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
	ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.
	The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:
			Fair Value		(Level 1)		(Level 2)		(Level 3)
	31-Mar-14
	Assets:
	Certificates of Deposit		$	10,004,345	$	10,004,345	$	-	$	-
	Money Market Fund			8,662,373		8,662,373		-		-
	Total		$	18,666,718	$	18,666,718	$	-	$	-
	31-Dec-13
	Assets:
	Certificates of Deposit		$	15,003,472	$	15,003,472	$	-	$	-
	Money Market Fund			7,597,730		7,597,730		-		-
	Total		$	22,601,202	$	22,601,202	$	-	$	-
	Non-cash derivative instrument charge
	During the three months ended March 31, 2013, the Company recognized a non-cash derivative instrument charge of  $6,725,797. The charge related to an obligation to issue additional shares of common stock and warrants to certain existing stockholders who participated in early closings of a private placement that started in 2012 and closed on April 29, 2013. This contractual obligation represented a derivative liability as March 31, 2013 and was fair valued at $6,725,797 using significant unobservable inputs (Level 3).

Other_Receivables

Other Receivables	3 Months Ended
	Mar. 31, 2014
Other Receivables, Net, Current [Abstract]	'
Other Receivable [Text Block]	'
	4	Other Receivables
	Other receivables as of March 31, 2014 and December 31, 2013, consists of the following:
			March 31, 2014		December 31, 2013
	Receivables related to the sale of New Jersey net operating losses		$	-	$	1,412,302
	Other receivables			5,856		5,011
			$	5,856	$	1,417,313

Other_Current_Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Other Current Assets [Text Block]	'
	5	Other Current Assets
	Other current assets as of March 31, 2014 and December 31, 2013 consist of the following:
			March 31, 2014		December 31, 2013
	Clinical trial materials		$	484,320	$	468,389

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Property Plant And Equipment Disclosure [Text Block]	'
	6	Property and Equipment
	Property and equipment as of March 31, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:
			March 31, 2014		December 31, 2013
	Computer and equipment		$	138,934	$	136,498
	Furniture and office equipment			96,457		96,457
	Laboratory equipment			1,760,633		1,760,633
	Capital lease equipment			155,523		155,523
	Leaseholds			37,789		37,789
				2,189,336		2,186,900
	Less: Accumulated depreciation			-1,096,057		-1,048,321
			$	1,093,279	$	1,138,579
	During the three months ended March 31, 2014 and March 31, 2013, depreciation and amortization expense was $47,735 and $47,588 respectively.
	In February 2012, the Company closed a laboratory in Canada and consigned certain property and equipment for sale with net book value of $507,622. At March 31, 2014 and December 31, 2013, the net book value of the remaining consigned equipment was $74,086 and consisted solely of scientific equipment, which is presented as assets held for sale on the consolidated balance sheet.
	During three months ended March 31, 2013 assets held for sale with a net book value of $43,703 were sold for proceeds of $29,976 resulting in a loss on disposal of $13,727. There were no disposals during the three months ended March 31, 2014.

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Accounts Payable And Accrued Liabilities Disclosure [Text Block]	'
	7	Accrued Liabilities
	Accrued liabilities as of March 31, 2014 and December 31, 2013 consists of the following:
			March 31, 2014		December 31, 2013
	Accrued bonuses		$	249,671	$	624,472
	Accrued salaries and vacation			217,891		143,484
	Accrued professional fees			91,627		30,911
	Accrued clinical trial expenses			447,889		636,497
	Accrued drug manufacturing expenses			124,481		-
	Accrued other			126,332		195,445
			$	1,257,891	$	1,630,809

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	8	Stock Based Compensation
	The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2014:
			Number of			Exercise
			options			price
	31-Dec-13			2,578,252		$	2.98
	Granted			394,500			3.23
	Exercised			-42,936			2.34
	Cancelled			-9,269			3.37
	31-Mar-14			2,920,547		$	3.02
	Exercisable at March 31, 2014			716,371		$	2.51
	The following table provides information regarding stock options activity for the three months ended March 31, 2014 and 2013:
			Three months ended
			March 31
			2014				2013
	Stock compensation expense recognized		$	302,982			$	4,276
	Weighted average grant-date fair value of stock options issued (per share)		$	2.78
	Grant-date fair value of stock options issued		$	1,096,710
	Volatility			115	%
	Risk-free interest rate			2.1	%
	Dividend yield			0	%
	Expected life in years			6.3
	Intrinsic value of stock options exercised		$	38,892
	The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.
	The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At March 31, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $4,439,416 and 3.3 years, respectively.

Geographic_Segment_Information

Geographic Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	9	Geographic Segment Information
	The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.
			Total Assets
			March 31, 2014		December 31, 2013
	United States		$	21,415,807	$	26,190,516
	Canada			587,022		284,563
	Germany			960,776		997,671
	Total Assets		$	22,963,605	$	27,472,750
			Net Loss
			Three months ended
			March 31
			2014		2013
	United States		$	-3,654,881	$	-8,749,635
	Canada			-622,620		-934,313
	Total Net Loss		$	-4,277,501	$	-9,683,948

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments And Contingencies Disclosure [Text Block]	'
	10	Commitments and Contingencies
	In February 2013, the Company renewed its office lease agreements for office space in Vancouver, British Columbia, effective April 1, 2013 which expires in June 2016. The remaining minimum lease payments as of March 31, 2014 totaled $145,000.
	In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of March 31, 2014 totaled $598,419. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement, which amount will be reduced by $40,000 per year on each of December 1, 2014, 2015, and 2016 and by $60,000 on December 1, 2017.
	The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in Celator’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.
	The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.
	In consideration of funding by the Leukemia & Lymphoma Society ® (“LLS”) and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	11	Subsequent Events
	On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Growth Capital, Inc.  The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-two months including an initial interest-only period of twelve months after closing.The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015. The interest rate is the greater of 9.75% or an adjusted rate based upon the US prime rate. The interest only period is extendable to October 31, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share. The funds will be used to provide general working capital.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Basis of consolidation: The consolidated financial statements include the accounts of Celator and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	the following table provides the assets carried at fair value:
		Fair Value		(Level 1)		(Level 2)		(Level 3)
	31-Mar-14
	Assets:
	Certificates of Deposit	$	10,004,345	$	10,004,345	$	-	$	-
	Money Market Fund		8,662,373		8,662,373		-		-
	Total	$	18,666,718	$	18,666,718	$	-	$	-
	31-Dec-13
	Assets:
	Certificates of Deposit	$	15,003,472	$	15,003,472	$	-	$	-
	Money Market Fund		7,597,730		7,597,730		-		-
	Total	$	22,601,202	$	22,601,202	$	-	$	-

Other_Receivables_Tables

Other Receivables (Tables)	3 Months Ended
	Mar. 31, 2014
Other Receivables, Net, Current [Abstract]	'
Schedule Of Other Receivables And Other Assets [Table Text Block]	'
	Other receivables as of March 31, 2014 and December 31, 2013, consists of the following:
		March 31, 2014		December 31, 2013
	Receivables related to the sale of New Jersey net operating losses	$	-	$	1,412,302
	Other receivables		5,856		5,011
		$	5,856	$	1,417,313

Other_Current_Assets_Tables

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of Other Current Assets [Table Text Block]	'
	Other current assets as of March 31, 2014 and December 31, 2013 consist of the following:
		March 31, 2014		December 31, 2013
	Clinical trial materials	$	484,320	$	468,389

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment as of March 31, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:
		March 31, 2014		December 31, 2013
	Computer and equipment	$	138,934	$	136,498
	Furniture and office equipment		96,457		96,457
	Laboratory equipment		1,760,633		1,760,633
	Capital lease equipment		155,523		155,523
	Leaseholds		37,789		37,789
			2,189,336		2,186,900
	Less: Accumulated depreciation		-1,096,057		-1,048,321
		$	1,093,279	$	1,138,579

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities as of March 31, 2014 and December 31, 2013 consists of the following:
		March 31, 2014		December 31, 2013
	Accrued bonuses	$	249,671	$	624,472
	Accrued salaries and vacation		217,891		143,484
	Accrued professional fees		91,627		30,911
	Accrued clinical trial expenses		447,889		636,497
	Accrued drug manufacturing expenses		124,481		-
	Accrued other		126,332		195,445
		$	1,257,891	$	1,630,809

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2014:
		Number of			Exercise
		options			price
	31-Dec-13		2,578,252		$	2.98
	Granted		394,500			3.23
	Exercised		-42,936			2.34
	Cancelled		-9,269			3.37
	31-Mar-14		2,920,547		$	3.02
	Exercisable at March 31, 2014		716,371		$	2.51
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following table provides information regarding stock options activity for the three months ended March 31, 2014 and 2013:
		Three months ended
		March 31
		2014				2013
	Stock compensation expense recognized	$	302,982			$	4,276
	Weighted average grant-date fair value of stock options issued (per share)	$	2.78
	Grant-date fair value of stock options issued	$	1,096,710
	Volatility		115	%
	Risk-free interest rate		2.1	%
	Dividend yield		0	%
	Expected life in years		6.3
	Intrinsic value of stock options exercised	$	38,892

Geographic_Segment_Information1

Geographic Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The geographic information about total assets is based on the physical location of the assets.
		Total Assets
		March 31, 2014		December 31, 2013
	United States	$	21,415,807	$	26,190,516
	Canada		587,022		284,563
	Germany		960,776		997,671
	Total Assets	$	22,963,605	$	27,472,750
		Net Loss
		Three months ended
		March 31
		2014		2013
	United States	$	-3,654,881	$	-8,749,635
	Canada		-622,620		-934,313
	Total Net Loss	$	-4,277,501	$	-9,683,948

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Textual) (USD $)	3 Months Ended		173 Months Ended				0 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 1999	9-May-14	31-May-14	9-May-14
							Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
								Medium-term Notes [Member]	Medium-term Notes [Member]
Nature Of Business And Liquidity [Line Items]	'	'	'	'	'	'	'	'	'
Accumulated deficit	$136,742,871	'	$136,742,871	$132,465,370	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	20,812,057	8,110,389	20,812,057	23,589,516	9,648,008	0	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	15,000,000	15,000,000
Proceeds From Issuance Of Debt	$0	$0	$17,898,295	'	'	'	$10,000,000	$10,000,000	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets:	'	'
Total	$18,666,718	$22,601,202
Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Total	18,666,718	22,601,202
Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Total	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Total	0	0
Certificates of Deposit [Member]	'	'
Assets:	'	'
Certificates of Deposit	10,004,345	15,003,472
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Certificates of Deposit	10,004,345	15,003,472
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Certificates of Deposit	0	0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Certificates of Deposit	0	0
Money Market Funds [Member]	'	'
Assets:	'	'
Money Market Fund	8,662,373	7,597,730
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Money Market Fund	8,662,373	7,597,730
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Money Market Fund	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Assets:	'	'
Money Market Fund	$0	$0

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details Textual) (USD $)	3 Months Ended		173 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Non-cash derivative instrument charge	$0	$6,725,797	$7,473,108
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Non-cash derivative instrument charge	'	$6,725,797	'

Other_Receivables_Details

Other Receivables (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Other Receivables [Line Items]	'	'
Receivables related to the sale of New Jersey net operating losses	$0	$1,412,302
Other receivables	5,856	5,011
Other receivables, net	$5,856	$1,417,313

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Other Assets [Abstract]	'	'
Clinical trial materials	$484,320	$468,389

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$2,189,336	$2,186,900
Less: Accumulated depreciation	-1,096,057	-1,048,321
Property and equipment, net	1,093,279	1,138,579
Computer and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	138,934	136,498
Furniture and office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	96,457	96,457
Laboratory equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,760,633	1,760,633
Capital lease equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	155,523	155,523
Leaseholds [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$37,789	$37,789

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended		173 Months Ended				3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Feb. 29, 2012	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
					Scientific Equipment [Member]	Scientific Equipment [Member]	Assets Held for Sale [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'
Assets Held For Sale Long Lived	'	'	'	$507,622	$74,086	$74,086	'
Assets Disposals, Written Off Net Book Value	'	'	'	'	'	'	43,703
Proceeds from sale of assets	0	29,976	447,164	'	'	'	29,976
Loss on disposal of property and equipment	0	-13,727	-898,719	'	'	'	13,727
Depreciation And Amortization	$47,735	$47,588	$4,919,708	'	'	'	'

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]	'	'
Accrued bonuses	$249,671	$624,472
Accrued salaries and vacation	217,891	143,484
Accrued professional fees	91,627	30,911
Accrued clinical trial expenses	447,889	636,497
Accrued drug manufacturing expenses	124,481	0
Accrued other	126,332	195,445
Accrued liabilities	$1,257,891	$1,630,809

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Number of options, Beginning balance	2,578,252
Number of options, Granted	394,500
Number of options, Exercised	-42,936
Number of options, Cancelled	-9,269
Number of options, Ending balance	2,920,547
Number of options, Exercisable	716,371
Exercise price, Beginning balance	$2.98
Exercise price, Granted	$3.23
Exercise pice, Exercised	$2.34
Exercise price, Cancelled	$3.37
Exercise price, Ending balance	$3.02
Exercise price, Exercisable	$2.51

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	3 Months Ended		173 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Stock compensation expense recognized	$302,982	$4,276	$1,960,777
Weighted average grant-date fair value of stock options issued (per share)	$2.78	'	'
Grant-date fair value of stock options issued	1,096,710	'	'
Volatility	115.00%	'	'
Risk-free interest rate	2.10%	'	'
Dividend yield	0.00%	'	'
Expected life in years	'6 years 3 months 18 days	'	'
Intrinsic value of stock options exercised	$38,892	'	'

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details Textual) (Non vested Awards [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Non vested Awards [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$4,439,416
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'3 years 3 months 18 days

Geographic_Segment_Information2

Geographic Segment Information (Details) (USD $)	3 Months Ended		173 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Total Assets	$22,963,605	'	$22,963,605	$27,472,750
Total Net Loss	-4,277,501	-9,683,948	-136,742,871	'
United States [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Total Assets	21,415,807	'	21,415,807	26,190,516
Total Net Loss	-3,654,881	-8,749,635	'	'
Canada [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Total Assets	587,022	'	587,022	284,563
Total Net Loss	-622,620	-934,313	'	'
Germany [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Total Assets	$960,776	'	$960,776	$997,671

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Agreement termination notice period	'90 days
Rectification of default period	'60 days
Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Cash Payment Or Royalties on net sales	5.00%
Leukemia & Lymphoma Society Agreement [Member] | Phase 3 study [Member]	'
Loss Contingencies [Line Items]	'
Funding for project inventions	5,000,000
Leukemia & Lymphoma Society Agreement [Member] | Phase 2 study [Member]	'
Loss Contingencies [Line Items]	'
Funding for project inventions	4,100,000
Vancouver, British Columbia [Member]	'
Loss Contingencies [Line Items]	'
Operating Leases, Future Minimum Payments Due, Total	145,000
Lease Commencement Date	'2013-04-01
Lease Expiration Date	30-Jun-16
Ewing, New Jersey [Member]	'
Loss Contingencies [Line Items]	'
Operating Leases, Future Minimum Payments Due, Total	598,419
Letters of Credit Outstanding, Amount	200,000
Contractual Obligation of letter of credit payment as on December 1, 2014	40,000
Contractual Obligation of letter of credit payment as on December 1, 2015	40,000
Contractual Obligation of letter of credit payment as on December 1, 2016	40,000
Contractual Obligation of letter of credit payment as on December 1, 2017	60,000
Lease Commencement Date	'2013-06-01
Operating Lease Expiration Term	'60 months
British Columbia Cancer Agency [Member]	'
Loss Contingencies [Line Items]	'
Rectification of default period	'45 days
Minimum [Member] | Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Minimum [Member] | Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Number of times amount payable under research funding program	1.5
Maximum [Member] | Princeton University Agreement [Member]	'
Loss Contingencies [Line Items]	'
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] | Leukemia & Lymphoma Society Agreement [Member]	'
Loss Contingencies [Line Items]	'
Number of times amount payable under research funding program	3.55

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	3 Months Ended		173 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	9-May-14	Mar. 31, 2014	9-May-14	31-May-14
				Subsequent Event [Member]	Medium-term Notes [Member]	Medium-term Notes [Member]	Medium-term Notes [Member]
					Hercules Technology Growth Capital Inc [Member]	Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	$15,000,000	$15,000,000
Proceeds From Issuance Of Debt	$0	$0	$17,898,295	$10,000,000	'	'	$10,000,000
Debt Instrument, Term	'	'	'	'	'	'42 months	'
Debt Instrument, Interest Rate Terms	'	'	'	'The interest rate is the greater of 9.75% or an adjusted rate based upon the US prime rate.	'	'	'
Number of warrants to purchase common stock issued	'	'	'	158,006	'	'	'
Exercise price per share or per unit of warrants or rights issued	'	'	'	2.67	'	'	'
Subsequent Event, Date	9-May-14	'	'	'	'	'	'
Debt Instrument, Unused Borrowing Capacity, Description	'	'	'	'	'The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015.	'	'